Drugs / UB-313
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05477095 | Jul 2022 → Oct 2023 | migraine disorder | Vaxxinity, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UB-313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05477095 ↗ |
| Modality | Peptide | “A synthetic peptide-based immunotherapy” NCT05477095 ↗ |
| Route | Intramuscular | “intramuscular (IM) injection” NCT05477095 ↗ |